Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade
Despite remarkable therapeutic achievements in medicine, cardiovascular diseases remain the major cause of death in the new millennium. The cardiovascular disease continuum starts with risk factors such as hypertension, diabetes mellitus and lipid disorders, leading to coronary artery disease or lef...
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2001, 2001
|
| Edition: | 1st ed. 2001 |
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- 1 The Cardiovascular Continuum — Pathophysiology and Targets for Therapy
- 2 Anti-Adrenergic Therapy in Hypertensive Patients with Concomitant Disease
- 3 The Effects of ß-Blockade on the Cardiovascular System — Not All ß-Blockers are Created Equal
- 4 The Role of Multiple Adrenergic Blockade in Coronary Artery Disease and Myocardial Infarction
- 5 Epidemiology and Problems with Diagnosis of Heart Failure
- 6 The Future of the Diagnosis of Left Ventricular Dysfunction and Heart Failure
- 7 Are All ß-Blockers the Same for Heart Failure? Insights from Clinical Trials and Future Research Directions
- 8 The Therapeutic Role of ß-Adrenoceptor-Blocking Agents in Severe Heart Failure
- 9 Tolerability of Anti-Adrenergic Treatment of Congestive Heart Failure in Daily Practice
- 10 Adrenergic Blockade in Heart Failure — Official Guidelines and Practical Recommendations on Optimal Use
- 11 The Future of Heart Failure Management